A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Inclusion Criteria:
Aged ≥ 18 years.
Clinical diagnosis of nonsegmental vitiligo and meet the following:
Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit.
Willingness to avoid pregnancy or fathering children.
Exclusion Criteria:
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Santa Monica, California 90404, United States
Sunnyvale, California 94086, United States
Richmond, Virginia 23226, United States
Brussel/ Brussels/bruxelles, 01070, Belgium
North YORK, Ontario M2M 4J5, Canada
Shinagawa-ku, 141-8625, Japan
Shinjuku-ku, 160-0023, Japan
Deleg. Cuauhtemoc, 06700, Mexico
Monterrey, 64660, Mexico
Providencia 5TA Seccion, Mexico
Amsterdam, 1105 AZ, Netherlands
Wrocaw, 54144, Poland